



## Clinical trial results:

### A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2021-001200-15 |
| Trial protocol           | DE FR ES IT    |
| Global end of trial date | 08 May 2024    |

#### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v2 (current)     |
| This version publication date  | 28 February 2025 |
| First version publication date | 06 November 2024 |
| Version creation reason        |                  |

#### Trial information

##### Trial identification

|                       |                 |
|-----------------------|-----------------|
| Sponsor protocol code | ALXN1210-DM-310 |
|-----------------------|-----------------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04999020 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |                                                                                                                   |
|------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Sponsor organisation name    | Alexion Pharmaceuticals Inc.                                                                                      |
| Sponsor organisation address | 121 Seaport Boulevard, Boston, MA, United States, 02210                                                           |
| Public contact               | European Clinical Trial Information, Alexion Pharmaceuticals Inc., +35 3874162507, clinicaltrials.eu@alexion.com  |
| Scientific contact           | European Clinical Trial Information, Alexion Pharmaceuticals, Inc., +35 3874162507, clinicaltrials.eu@alexion.com |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |             |
|------------------------------------------------------|-------------|
| Analysis stage                                       | Final       |
| Date of interim/final analysis                       | 08 May 2024 |
| Is this the analysis of the primary completion data? | No          |
| Global end of trial reached?                         | Yes         |
| Global end of trial date                             | 08 May 2024 |
| Was the trial ended prematurely?                     | Yes         |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the study was to determine the effect of ravulizumab compared with placebo in the treatment of dermatomyositis (DM) based on improvement in Total Improvement Score (TIS) International Myositis Assessment and Clinical Studies Total Improvement Score (IMAC-TIS).

Protection of trial subjects:

This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the Declaration of Helsinki, Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, applicable International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines, and other applicable laws and regulations.

Background therapy: -

Evidence for comparator: -

|                                                           |                  |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment                          | 19 November 2021 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | Yes              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                       |
|--------------------------------------|-----------------------|
| Country: Number of subjects enrolled | France: 2             |
| Country: Number of subjects enrolled | Germany: 5            |
| Country: Number of subjects enrolled | Italy: 14             |
| Country: Number of subjects enrolled | Japan: 1              |
| Country: Number of subjects enrolled | Korea, Republic of: 4 |
| Country: Number of subjects enrolled | Spain: 2              |
| Country: Number of subjects enrolled | United Kingdom: 2     |
| Country: Number of subjects enrolled | United States: 8      |
| Worldwide total number of subjects   | 38                    |
| EEA total number of subjects         | 23                    |

Notes:

### Subjects enrolled per age group

|                                           |   |
|-------------------------------------------|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

|                                          |    |
|------------------------------------------|----|
| Newborns (0-27 days)                     | 0  |
| Infants and toddlers (28 days-23 months) | 0  |
| Children (2-11 years)                    | 0  |
| Adolescents (12-17 years)                | 0  |
| Adults (18-64 years)                     | 33 |
| From 65 to 84 years                      | 5  |
| 85 years and over                        | 0  |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study was planned to be conducted in 2 parts – Part A and Part B. The study was terminated early and participants were not enrolled into Part B. Therefore, results are presented for Part A of the study only. Part A consisted of a Randomized Controlled Period (RCP) and an Open-Label Extension (OLE) period.

### Period 1

|                              |                                    |
|------------------------------|------------------------------------|
| Period 1 title               | Randomized Controlled Period (RCP) |
| Is this the baseline period? | Yes                                |
| Allocation method            | Randomised - controlled            |
| Blinding used                | Double blind                       |
| Roles blinded                | Subject, Investigator              |

### Arms

|                              |                  |
|------------------------------|------------------|
| Are arms mutually exclusive? | Yes              |
| <b>Arm title</b>             | RCP: Ravulizumab |

Arm description:

Participants received a loading dose of ravulizumab on Day 1 followed by a maintenance dose at Week 2 and then ravulizumab once every 8 weeks (Q8W) during the 26-week RCP.

|                                        |                       |
|----------------------------------------|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | Ravulizumab           |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Ravulizumab per dosage and administration specified in the arm description.

|                  |              |
|------------------|--------------|
| <b>Arm title</b> | RCP: Placebo |
|------------------|--------------|

Arm description:

Participants received placebo on Day 1, and Weeks 2, 10, and 18 during the 26-week RCP.

|                                        |                       |
|----------------------------------------|-----------------------|
| Arm type                               | Placebo               |
| Investigational medicinal product name | Placebo               |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Placebo per administration specified in the arm description.

| Number of subjects in period 1        | RCP: Ravulizumab | RCP: Placebo |
|---------------------------------------|------------------|--------------|
| Started                               | 26               | 12           |
| Received at Least 1 Dose of Treatment | 26               | 12           |
| Completed                             | 22               | 9            |
| Not completed                         | 4                | 3            |
| Consent withdrawn by subject          | 1                | 2            |
| Physician decision                    | 1                | 1            |
| Adverse event, non-fatal              | 2                | -            |

## Period 2

|                              |                                   |
|------------------------------|-----------------------------------|
| Period 2 title               | Open-Label Extension (OLE) Period |
| Is this the baseline period? | No                                |
| Allocation method            | Not applicable                    |
| Blinding used                | Not blinded                       |

## Arms

|                              |                                 |
|------------------------------|---------------------------------|
| Are arms mutually exclusive? | Yes                             |
| <b>Arm title</b>             | OLE: Ravulizumab to Ravulizumab |

### Arm description:

Participants who received ravulizumab during the RCP continued to receive ravulizumab during the 130-week OLE. Participants received a blinded ravulizumab dose at Week 26, a maintenance dose at Week 28, then ravulizumab Q8W for the remainder of the OLE period.

|                                        |                       |
|----------------------------------------|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | Ravulizumab           |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

### Dosage and administration details:

Ravulizumab per dosage and administration specified in the arm description.

|                  |                             |
|------------------|-----------------------------|
| <b>Arm title</b> | OLE: Placebo to Ravulizumab |
|------------------|-----------------------------|

### Arm description:

Participants who received placebo during the RCP received ravulizumab during the 130-week OLE. Participants received a blinded ravulizumab dose at Week 26, a maintenance dose at Week 28, then ravulizumab Q8W for the remainder of the OLE period.

|                                        |                       |
|----------------------------------------|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | Ravulizumab           |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

### Dosage and administration details:

Ravulizumab per dosage and administration specified in the arm description.

| <b>Number of subjects in period 2</b> | OLE: Ravulizumab to Ravulizumab | OLE: Placebo to Ravulizumab |
|---------------------------------------|---------------------------------|-----------------------------|
| Started                               | 22                              | 9                           |
| Received at Least 1 Dose of Treatment | 22                              | 9                           |
| Completed                             | 0                               | 0                           |
| Not completed                         | 22                              | 9                           |
| Consent withdrawn by subject          | 3                               | 3                           |
| Physician decision                    | 1                               | -                           |
| Adverse event, non-fatal              | -                               | 2                           |
| Study Terminated by Sponsor           | 17                              | 4                           |
| Lost to follow-up                     | 1                               | -                           |

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                             |                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Reporting group title                                                                                                                                                       | RCP: Ravulizumab |
| Reporting group description:                                                                                                                                                |                  |
| Participants received a loading dose of ravulizumab on Day 1 followed by a maintenance dose at Week 2 and then ravulizumab once every 8 weeks (Q8W) during the 26-week RCP. |                  |
| Reporting group title                                                                                                                                                       | RCP: Placebo     |
| Reporting group description:                                                                                                                                                |                  |
| Participants received placebo on Day 1, and Weeks 2, 10, and 18 during the 26-week RCP.                                                                                     |                  |

| Reporting group values                             | RCP: Ravulizumab | RCP: Placebo | Total |
|----------------------------------------------------|------------------|--------------|-------|
| Number of subjects                                 | 26               | 12           | 38    |
| Age categorical                                    |                  |              |       |
| Units: Subjects                                    |                  |              |       |
| In utero                                           | 0                | 0            | 0     |
| Preterm newborn infants (gestational age < 37 wks) | 0                | 0            | 0     |
| Newborns (0-27 days)                               | 0                | 0            | 0     |
| Infants and toddlers (28 days-23 months)           | 0                | 0            | 0     |
| Children (2-11 years)                              | 0                | 0            | 0     |
| Adolescents (12-17 years)                          | 0                | 0            | 0     |
| Adults (18-64 years)                               | 24               | 9            | 33    |
| From 65-84 years                                   | 2                | 3            | 5     |
| 85 years and over                                  | 0                | 0            | 0     |
| Age Continuous                                     |                  |              |       |
| Units: years                                       |                  |              |       |
| arithmetic mean                                    | 50.7             | 59.3         | -     |
| standard deviation                                 | ± 10.38          | ± 9.31       | -     |
| Sex: Female, Male                                  |                  |              |       |
| Units: participants                                |                  |              |       |
| Female                                             | 18               | 9            | 27    |
| Male                                               | 8                | 3            | 11    |
| Ethnicity (NIH/OMB)                                |                  |              |       |
| Units: Subjects                                    |                  |              |       |
| Hispanic or Latino                                 | 3                | 2            | 5     |
| Not Hispanic or Latino                             | 23               | 10           | 33    |
| Unknown or Not Reported                            | 0                | 0            | 0     |
| Race (NIH/OMB)                                     |                  |              |       |
| Units: Subjects                                    |                  |              |       |
| American Indian or Alaska Native                   | 0                | 0            | 0     |
| Asian                                              | 4                | 2            | 6     |
| Native Hawaiian or Other Pacific Islander          | 0                | 0            | 0     |
| Black or African American                          | 3                | 0            | 3     |
| White                                              | 18               | 10           | 28    |
| More than one race                                 | 0                | 0            | 0     |
| Unknown or Not Reported                            | 1                | 0            | 1     |



## End points

### End points reporting groups

|                                                                                                                                                                                                                                                                                                      |                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| Reporting group title                                                                                                                                                                                                                                                                                | RCP: Ravulizumab                |
| Reporting group description:<br>Participants received a loading dose of ravulizumab on Day 1 followed by a maintenance dose at Week 2 and then ravulizumab once every 8 weeks (Q8W) during the 26-week RCP.                                                                                          |                                 |
| Reporting group title                                                                                                                                                                                                                                                                                | RCP: Placebo                    |
| Reporting group description:<br>Participants received placebo on Day 1, and Weeks 2, 10, and 18 during the 26-week RCP.                                                                                                                                                                              |                                 |
| Reporting group title                                                                                                                                                                                                                                                                                | OLE: Ravulizumab to Ravulizumab |
| Reporting group description:<br>Participants who received ravulizumab during the RCP continued to receive ravulizumab during the 130-week OLE. Participants received a blinded ravulizumab dose at Week 26, a maintenance dose at Week 28, then ravulizumab Q8W for the remainder of the OLE period. |                                 |
| Reporting group title                                                                                                                                                                                                                                                                                | OLE: Placebo to Ravulizumab     |
| Reporting group description:<br>Participants who received placebo during the RCP received ravulizumab during the 130-week OLE. Participants received a blinded ravulizumab dose at Week 26, a maintenance dose at Week 28, then ravulizumab Q8W for the remainder of the OLE period.                 |                                 |

### Primary: Number of Participants with International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS-TIS) (TIS40) Response at Week 26 of the Randomized Controlled Period

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Number of Participants with International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS-TIS) (TIS40) Response at Week 26 of the Randomized Controlled Period |
| End point description:<br>Data are presented for the number of participants with a TIS40 response, defined as an IMACS-TIS score $\geq 40$ at Week 26. IMACS-TIS is a clinical instrument that encompasses 6 core set measure (CSMs) (physician, patient, extra-muscular global activity, muscle strength, Health Assessment Questionnaire [HAQ], and muscle enzyme levels). A Total Improvement Score (TIS: 0–100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. A higher score indicated greater improvement. TIS40 was considered a moderate improvement score. Randomized Set, which included all randomized participants grouped by randomized treatment group. |                                                                                                                                                                                        |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Primary                                                                                                                                                                                |
| End point timeframe:<br>Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                        |

| End point values            | RCP: Ravulizumab | RCP: Placebo    |  |  |
|-----------------------------|------------------|-----------------|--|--|
| Subject group type          | Reporting group  | Reporting group |  |  |
| Number of subjects analysed | 26               | 12              |  |  |
| Units: participants         | 9                | 6               |  |  |

## Statistical analyses

|                                         |                                    |
|-----------------------------------------|------------------------------------|
| <b>Statistical analysis title</b>       | Ravulizumab vs placebo             |
| Comparison groups                       | RCP: Ravulizumab v RCP: Placebo    |
| Number of subjects included in analysis | 38                                 |
| Analysis specification                  | Pre-specified                      |
| Analysis type                           | superiority                        |
| P-value                                 | = 0.4192                           |
| Method                                  | Barnard's unconditional exact test |
| Parameter estimate                      | Difference in response rates       |
| Point estimate                          | -15.38                             |
| Confidence interval                     |                                    |
| level                                   | Other: 80 %                        |
| sides                                   | 2-sided                            |
| lower limit                             | -38.55                             |
| upper limit                             | 8.48                               |

## Secondary: TIS at Week 26

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | TIS at Week 26 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                |
| TIS scores ranged from 0–100 with higher scores indicating a greater improvement. Scores were determined by summing scores in each of the 6 CSMs of the IMAC (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). Clinically meaningful thresholds for improvement were defined as $\geq 20$ point improvement response on IMACS-TIS (TIS20; mild), $\geq 40$ point improvement response on IMACS TIS (TIS40; moderate) and $\geq 60$ point improvement response on IMACS-TIS (TIS60; severe). Scores were based on the improvement and relative weight of each CSM. Data are presented for TIS (least squares mean) at Week 26. Randomized Set, which included all randomized participants grouped by randomized treatment group. Number of participants analyzed = participants with evaluable data for the outcome measure. |                |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Secondary      |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                |
| Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                |

| End point values                    | RCP:<br>Ravulizumab     | RCP: Placebo            |  |  |
|-------------------------------------|-------------------------|-------------------------|--|--|
| Subject group type                  | Reporting group         | Reporting group         |  |  |
| Number of subjects analysed         | 25                      | 12                      |  |  |
| Units: scores on a scale            |                         |                         |  |  |
| least squares mean (standard error) | 31.16 ( $\pm$<br>4.185) | 43.28 ( $\pm$<br>6.650) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline In Cutaneous Dermatomyositis Disease Area And Severity Index (CDASI) Activity Score at Week 26

|                 |                                                                                                                     |
|-----------------|---------------------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline In Cutaneous Dermatomyositis Disease Area And Severity Index (CDASI) Activity Score at Week 26 |
|-----------------|---------------------------------------------------------------------------------------------------------------------|

---

**End point description:**

The CDASI is an instrument that separately measures activity and damage in the skin of dermatomyositis (DM) participants. It is a 1-page instrument that contains 3 activity measures (erythema, scale, and erosion/ulceration) and 2 damage measures (poikiloderma and calcinosis). CDASI score is calculated by rating the severity of skin disease in 15 anatomical locations on the body based on activity and damage components. CDASI was completed by the Clinician/Clinician-Investigator. Total CDASI scores ranged from 0-100, higher scores = greater disease severity. Change from baseline in CDASI Total Activity Score at Week 26 was analyzed using a mixed model repeated measures (MMRM). The MMRM model included the observed Total Activity Score values at post baseline visits (Week 26) as the dependent variable. Randomized Set, which included all randomized participants grouped by randomized treatment group. Number of participants analyzed = participants with evaluable data for the outcome measure.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

End point timeframe:

Baseline, Week 26

---

| End point values                    | RCP:<br>Ravulizumab | RCP: Placebo       |  |  |
|-------------------------------------|---------------------|--------------------|--|--|
| Subject group type                  | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed         | 25                  | 12                 |  |  |
| Units: scores on a scale            |                     |                    |  |  |
| least squares mean (standard error) | -3.80 (±<br>1.249)  | -7.47 (±<br>2.021) |  |  |

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Number of Participants with Response Related to Muscle Enzymes: Normalization of Most Abnormal Baseline Enzyme at Week 26**

---

|                 |                                                                                                                           |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Response Related to Muscle Enzymes: Normalization of Most Abnormal Baseline Enzyme at Week 26 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|

---

End point description:

Laboratory tests were conducted to measure serum activities of muscle associated enzymes including creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and aldolase. Data are presented for the number of participants who had an abnormal muscle enzyme at baseline that had been normalized at Week 26. Randomized Set, which included all randomized participants grouped by randomized treatment group.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

End point timeframe:

Baseline, Week 26

---

| End point values            | RCP:<br>Ravulizumab | RCP: Placebo    |  |  |
|-----------------------------|---------------------|-----------------|--|--|
| Subject group type          | Reporting group     | Reporting group |  |  |
| Number of subjects analysed | 26                  | 12              |  |  |
| Units: participants         | 4                   | 1               |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline In IMACS CSMs: Extra-Muscular Disease Activity Based on Myositis Disease Activity Assessment Tool (MDAAT) at Week 26

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Change from Baseline In IMACS CSMs: Extra-Muscular Disease Activity Based on Myositis Disease Activity Assessment Tool (MDAAT) at Week 26 |
| End point description:<br>The MDAAT assesses disease activity of extra-muscular organ systems and muscles in participants with DM. The validated MDAAT tool measures the degree of disease activity of extra-muscular organ systems and muscle on a 0-10 centimeter (cm) visual analog scale (VAS). Extra-muscular activity ranged between 0 and 10, where, 0 cm = absent and 10 cm = maximum disease activity. Randomized Set, which included all randomized participants grouped by randomized treatment group. Number of participants analyzed = participants with evaluable data for the outcome measure. |                                                                                                                                           |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Secondary                                                                                                                                 |
| End point timeframe:<br>Baseline, Week 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                           |

| End point values                    | RCP:<br>Ravulizumab | RCP: Placebo       |  |  |
|-------------------------------------|---------------------|--------------------|--|--|
| Subject group type                  | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed         | 25                  | 12                 |  |  |
| Units: scores on a scale            |                     |                    |  |  |
| least squares mean (standard error) | -0.92 (±<br>0.383)  | -2.13 (±<br>0.614) |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline In IMACS CSMs: Physician Global Activity Assessment at Week 26

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Change from Baseline In IMACS CSMs: Physician Global Activity Assessment at Week 26 |
| End point description:<br>The physician global activity assessment provides an overall rating of disease activity related to myositis. Disease activity is judged by the physician based on all information available at the time of evaluation, including the participant's appearance, medical history, physical examination, laboratory testing, and prescribed medical therapy. The global disease activity score is recorded on a 10-cm VAS, where 0 cm= no evidence of disease activity and 10 cm= extremely severe disease activity. Randomized Set, which included all randomized participants grouped by randomized treatment group. Number of |                                                                                     |

participants analyzed = participants with evaluable data for the outcome measure.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Baseline, Week 26    |           |

| End point values                    | RCP:<br>Ravulizumab     | RCP: Placebo            |  |  |
|-------------------------------------|-------------------------|-------------------------|--|--|
| Subject group type                  | Reporting group         | Reporting group         |  |  |
| Number of subjects analysed         | 25                      | 12                      |  |  |
| Units: scores on a scale            |                         |                         |  |  |
| least squares mean (standard error) | -1.18 ( $\pm$<br>0.413) | -1.97 ( $\pm$<br>0.649) |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline In IMACS CSMs: Manual Muscle Testing Subset 8 Muscles (MMT-8) at Week 26

|                 |                                                                                               |
|-----------------|-----------------------------------------------------------------------------------------------|
| End point title | Change from Baseline In IMACS CSMs: Manual Muscle Testing Subset 8 Muscles (MMT-8) at Week 26 |
|-----------------|-----------------------------------------------------------------------------------------------|

End point description:

The purpose of the MMT-8 was to measure muscle strength as part of the physical examination. It included a subset of 8 muscle groups: neck flexors, deltoids, biceps, wrist, extensors, gluteus maximus and medius, quadriceps, and ankle dorsiflexors. Total MMT8 scores ranged from 0 (lowest strength) to 150 (highest strength). Randomized Set, which included all randomized participants grouped by randomized treatment group. Number of participants analyzed = participants with evaluable data for the outcome measure.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Baseline, Week 26    |           |

| End point values                    | RCP:<br>Ravulizumab | RCP: Placebo       |  |  |
|-------------------------------------|---------------------|--------------------|--|--|
| Subject group type                  | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed         | 25                  | 12                 |  |  |
| Units: scores on a scale            |                     |                    |  |  |
| least squares mean (standard error) | 9.5 ( $\pm$ 1.85)   | 12.6 ( $\pm$ 2.98) |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline In IMACS CSMs: Patient Global Activity

## Assessment at Week 26

|                 |                                                                                   |
|-----------------|-----------------------------------------------------------------------------------|
| End point title | Change from Baseline In IMACS CSMs: Patient Global Activity Assessment at Week 26 |
|-----------------|-----------------------------------------------------------------------------------|

### End point description:

The patient global activity assessment provides an overall rating of disease activity related to myositis from the participant's perspective. Participants were asked to consider all of the active inflammation in their own muscles, skin, joints, intestines, heart, lungs, or other parts of the body that can improve with treatment. The patient global disease activity score was recorded on a 10-cm VAS that contained a smiley face at the 0-cm anchor and a sad face at the 10 cm anchor to help participants understand the scale. Scores ranged from 0 (no evidence of disease activity) to 10 (extremely active or severe disease activity). Randomized Set, which included all randomized participants grouped by randomized treatment group. Number of participants analyzed = participants with evaluable data for the outcome measure.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

### End point timeframe:

Baseline, Week 26

| End point values                    | RCP:<br>Ravulizumab | RCP: Placebo       |  |  |
|-------------------------------------|---------------------|--------------------|--|--|
| Subject group type                  | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed         | 25                  | 12                 |  |  |
| Units: scores on a scale            |                     |                    |  |  |
| least squares mean (standard error) | -1.43 (±<br>0.432)  | -1.12 (±<br>0.699) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline In IMACS CSMs: Health Assessment Questionnaire (HAQ) at Week 26

|                 |                                                                                      |
|-----------------|--------------------------------------------------------------------------------------|
| End point title | Change from Baseline In IMACS CSMs: Health Assessment Questionnaire (HAQ) at Week 26 |
|-----------------|--------------------------------------------------------------------------------------|

### End point description:

The HAQ is a brief self-report questionnaire that assesses physical function pertaining to activities of daily living in a variety of domains. The HAQ includes 20 questions relating to 8 domains of function: dressing and grooming, arising, eating, walking, hygiene, reach, grip and usual activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific subcategory items. The standard disability score is calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do), with higher values indicating higher disability. Randomized Set, which included all randomized participants grouped by randomized treatment group. Number of participants analyzed = participants with evaluable data for the outcome measure.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

### End point timeframe:

Baseline, Week 26

| End point values                    | RCP:<br>Ravulizumab         | RCP: Placebo                |  |  |
|-------------------------------------|-----------------------------|-----------------------------|--|--|
| Subject group type                  | Reporting group             | Reporting group             |  |  |
| Number of subjects analysed         | 25                          | 12                          |  |  |
| Units: scores on a scale            |                             |                             |  |  |
| least squares mean (standard error) | -0.1289 ( $\pm$<br>0.08607) | -0.4188 ( $\pm$<br>0.13676) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with CDASI Response ( $\geq 7$ -point Improvement) at Week 26

|                 |                                                                                      |
|-----------------|--------------------------------------------------------------------------------------|
| End point title | Number of Participants with CDASI Response ( $\geq 7$ -point Improvement) at Week 26 |
|-----------------|--------------------------------------------------------------------------------------|

End point description:

The CDASI is an instrument that separately measures activity and damage in the skin of dermatomyositis (DM) participants. It is a 1-page instrument that contains 3 activity measures (erythema, scale, and erosion/ulceration) and 2 damage measures (poikiloderma and calcinosis). CDASI score is calculated by rating the severity of skin disease in 15 anatomical locations on the body based on the activity and damage components. CDASI was completed by the Clinician or Clinician-Investigator while examining the participant. Total CDASI scores ranged from 0-100, with higher scores indicating a greater disease severity.

Data are presented for the number of participants with a CDASI response. Response was defined as a  $\geq 7$  point improvement in participants who did not have an intercurrent event at or prior to the relevant timepoint. Randomized Set, which included all randomized participants grouped by randomized treatment group.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 26

| End point values            | RCP:<br>Ravulizumab | RCP: Placebo    |  |  |
|-----------------------------|---------------------|-----------------|--|--|
| Subject group type          | Reporting group     | Reporting group |  |  |
| Number of subjects analysed | 26                  | 12              |  |  |
| Units: participants         | 6                   | 4               |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Cutaneous Dermatomyositis Activity Physician's Global Assessment (CDA-IGA) Response at Week 26

|                 |                                                                                                                            |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Cutaneous Dermatomyositis Activity Physician's Global Assessment (CDA-IGA) Response at Week 26 |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|

End point description:

CDA-IGA is a scale that was created to measure disease severity in participants with skin disease. It is a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) with morphologic descriptors for each score. The CDA-IGA was completed by the Investigator and was used to describe the overall appearance of lesions at a given time point. Data are presented for the number of participants with a CDA-IGA response at Week 26. A response was defined as participants with clear or almost clear skin (score of 0 or 1) who did not have an intercurrent event at or before the relevant timepoint. Randomized Set, which included all randomized participants grouped by randomized treatment group.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 26              |           |

| End point values            | RCP:<br>Ravulizumab | RCP: Placebo    |  |  |
|-----------------------------|---------------------|-----------------|--|--|
| Subject group type          | Reporting group     | Reporting group |  |  |
| Number of subjects analysed | 26                  | 12              |  |  |
| Units: participants         | 5                   | 2               |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with $\geq$ 20-Point Improvement Response on IMACS-TIS (TIS20) Response at Week 26

|                 |                                                                                                           |
|-----------------|-----------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with $\geq$ 20-Point Improvement Response on IMACS-TIS (TIS20) Response at Week 26 |
|-----------------|-----------------------------------------------------------------------------------------------------------|

End point description:

TIS20 was defined as a  $\geq$ 20-point improvement response on IMACS-TIS. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0–100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS20 is considered a mild improvement score. Randomized Set, which included all randomized participants grouped by randomized treatment group.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 26              |           |

| End point values            | RCP:<br>Ravulizumab | RCP: Placebo    |  |  |
|-----------------------------|---------------------|-----------------|--|--|
| Subject group type          | Reporting group     | Reporting group |  |  |
| Number of subjects analysed | 26                  | 12              |  |  |
| Units: participants         | 14                  | 9               |  |  |

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Number of Participants with  $\geq$  60-Point Improvement Response on IMACS-TIS (TIS60) Response at Week 26**

---

|                 |                                                                                                           |
|-----------------|-----------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with $\geq$ 60-Point Improvement Response on IMACS-TIS (TIS60) Response at Week 26 |
|-----------------|-----------------------------------------------------------------------------------------------------------|

End point description:

TIS60 was defined as a  $\geq$ 60-point improvement response on IMACS-TIS. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0–100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS60 is considered a severe improvement score. Randomized Set, which included all randomized participants grouped by randomized treatment group.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 26

---

| End point values            | RCP:<br>Ravulizumab | RCP: Placebo    |  |  |
|-----------------------------|---------------------|-----------------|--|--|
| Subject group type          | Reporting group     | Reporting group |  |  |
| Number of subjects analysed | 26                  | 12              |  |  |
| Units: participants         | 3                   | 2               |  |  |

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Time to First Response of TIS20, TIS40, or TIS60**

---

|                 |                                                  |
|-----------------|--------------------------------------------------|
| End point title | Time to First Response of TIS20, TIS40, or TIS60 |
|-----------------|--------------------------------------------------|

End point description:

TIS20, 40 and 60 were defined as a  $\geq$ 20,  $\geq$ 40 and  $\geq$ 60-point improvement response on IMACS-TIS respectively. TIS20, 40 and 60 were considered mild, moderate and severe improvement scores respectively. The median time to TIS20, TIS40, and TIS60 was defined at the time in which 50% of the participants experienced TIS20, TIS40, or TIS60, respectively, based on a Kaplan-Meier analysis. 99999=As fewer than 50% of the participants experienced the event of TIS40 and the median time to TIS40 event was close to the maximum follow-up period, there was not enough information on longer follow-up times to estimate the upper bound of the confidence interval. 9999= <50% of the participants experienced TIS60 response during the RCP (the Week 26 period), the median time could not be estimated along with the associated 80% confidence interval(s) using Kaplan-Meier analysis.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through Week 26

---

| End point values                 | RCP:<br>Ravulizumab    | RCP: Placebo          |  |  |
|----------------------------------|------------------------|-----------------------|--|--|
| Subject group type               | Reporting group        | Reporting group       |  |  |
| Number of subjects analysed      | 26                     | 12                    |  |  |
| Units: weeks                     |                        |                       |  |  |
| median (confidence interval 80%) |                        |                       |  |  |
| Time to TIS20 (n=17, n=10)       | 10.43 (10.14 to 17.86) | 10.14 (2.14 to 10.14) |  |  |
| Time to TIS40 (n=10, n=6)        | 25.86 (18.14 to 99999) | 26.0 (10.14 to 26.29) |  |  |
| Time to TIS60 (n=3, n=2)         | 9999 (9999 to 9999)    | 9999 (26.14 to 9999)  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Clinical Worsening (CW) During the RCP At 2 Consecutive Visits

|                 |                                                                                            |
|-----------------|--------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Clinical Worsening (CW) During the RCP At 2 Consecutive Visits |
|-----------------|--------------------------------------------------------------------------------------------|

End point description:

CW was defined as one of the following:

- Physician's global activity VAS worsening  $\geq 2$  cm and MMT-8 worsening  $\geq 20\%$  compared to baseline
- Global extra muscular activity worsening  $\geq 2$  cm on the MDAAT VAS compared to baseline
- Any 3 of 5 CSMs (excluding muscle enzymes) worsening by  $\geq 30\%$  compared to baseline

Data are presented for the number of participants with clinical worsening during the RCP at 2 consecutive visits. Randomized Set, which included all randomized participants grouped by randomized treatment group.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through Week 26

| End point values            | RCP:<br>Ravulizumab | RCP: Placebo    |  |  |
|-----------------------------|---------------------|-----------------|--|--|
| Subject group type          | Reporting group     | Reporting group |  |  |
| Number of subjects analysed | 26                  | 12              |  |  |
| Units: participants         | 2                   | 0               |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants who Received Acute Rescue Therapy with Standard DM Treatment

|                 |                                                                                     |
|-----------------|-------------------------------------------------------------------------------------|
| End point title | Number of Participants who Received Acute Rescue Therapy with Standard DM Treatment |
|-----------------|-------------------------------------------------------------------------------------|

---

**End point description:**

Acute rescue therapy with standard DM treatment included an increased dose of a medication that was being taken for DM or the initiation of a new DM treatment (glucocorticoid and/or immunosuppressive/immunomodulatory therapy [ISTs]). Data are presented for the number of participants who received acute rescue therapy with standard DM treatment. Randomized Set, which included all randomized participants grouped by randomized treatment group.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

**End point timeframe:**

Baseline through Week 26

---

| <b>End point values</b>     | RCP:<br>Ravulizumab | RCP: Placebo    |  |  |
|-----------------------------|---------------------|-----------------|--|--|
| Subject group type          | Reporting group     | Reporting group |  |  |
| Number of subjects analysed | 26                  | 12              |  |  |
| Units: participants         | 2                   | 0               |  |  |

---

**Statistical analyses**

No statistical analyses for this end point

---

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to approximately 130 weeks

Adverse event reporting additional description:

Safety Set for RCP = participants who received  $\geq 1$  dose of treatment. Participants were analyzed according to treatment received. One participant who was randomized to ravulizumab during RCP received placebo and was analyzed in placebo group. OLE Set for the OLE period= participants who received at least 1 dose of ravulizumab from Week 26

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 27.0 |
|--------------------|------|

### Reporting groups

|                       |                  |
|-----------------------|------------------|
| Reporting group title | RCP: Ravulizumab |
|-----------------------|------------------|

Reporting group description:

Participants received a loading dose of ravulizumab on Day 1 followed by a maintenance dose at Week 2 and then ravulizumab once every 8 weeks (Q8W) during the 26-week RCP.

|                       |                                 |
|-----------------------|---------------------------------|
| Reporting group title | OLE: Ravulizumab to Ravulizumab |
|-----------------------|---------------------------------|

Reporting group description:

Participants who received ravulizumab during the RCP continued to receive ravulizumab during the 130-week OLE. Participants received a blinded ravulizumab dose at Week 26, a maintenance dose at Week 28, then ravulizumab Q8W for the remainder of the OLE period.

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | OLE: Placebo to Ravulizumab |
|-----------------------|-----------------------------|

Reporting group description:

Participants who received placebo during the RCP received ravulizumab during the 130-week OLE. Participants received a blinded ravulizumab dose at Week 26, a maintenance dose at Week 28, then ravulizumab Q8W for the remainder of the OLE period.

|                       |              |
|-----------------------|--------------|
| Reporting group title | RCP: Placebo |
|-----------------------|--------------|

Reporting group description:

Participants received placebo on Day 1, and Weeks 2, 10, and 18 during the 26-week RCP.

| Serious adverse events                                              | RCP: Ravulizumab | OLE: Ravulizumab to Ravulizumab | OLE: Placebo to Ravulizumab |
|---------------------------------------------------------------------|------------------|---------------------------------|-----------------------------|
| Total subjects affected by serious adverse events                   |                  |                                 |                             |
| subjects affected / exposed                                         | 2 / 25 (8.00%)   | 4 / 22 (18.18%)                 | 4 / 9 (44.44%)              |
| number of deaths (all causes)                                       | 0                | 0                               | 0                           |
| number of deaths resulting from adverse events                      |                  |                                 |                             |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                  |                                 |                             |
| Breast cancer                                                       |                  |                                 |                             |
| subjects affected / exposed                                         | 0 / 25 (0.00%)   | 0 / 22 (0.00%)                  | 1 / 9 (11.11%)              |
| occurrences causally related to treatment / all                     | 0 / 0            | 0 / 0                           | 0 / 1                       |
| deaths causally related to treatment / all                          | 0 / 0            | 0 / 0                           | 0 / 0                       |
| Vascular disorders                                                  |                  |                                 |                             |

|                                                      |                |                |                |
|------------------------------------------------------|----------------|----------------|----------------|
| Hypovolaemic shock                                   |                |                |                |
| subjects affected / exposed                          | 0 / 25 (0.00%) | 0 / 22 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                                    |                |                |                |
| Coronary artery stenosis                             |                |                |                |
| subjects affected / exposed                          | 0 / 25 (0.00%) | 0 / 22 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac failure                                      |                |                |                |
| subjects affected / exposed                          | 0 / 25 (0.00%) | 0 / 22 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Myocardial infarction                                |                |                |                |
| subjects affected / exposed                          | 0 / 25 (0.00%) | 0 / 22 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                             |                |                |                |
| Syncope                                              |                |                |                |
| subjects affected / exposed                          | 1 / 25 (4.00%) | 0 / 22 (0.00%) | 0 / 9 (0.00%)  |
| occurrences causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Blood and lymphatic system disorders                 |                |                |                |
| Agranulocytosis                                      |                |                |                |
| subjects affected / exposed                          | 0 / 25 (0.00%) | 1 / 22 (4.55%) | 0 / 9 (0.00%)  |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Anaemia                                              |                |                |                |
| subjects affected / exposed                          | 0 / 25 (0.00%) | 0 / 22 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| General disorders and administration site conditions |                |                |                |
| Impaired healing                                     |                |                |                |

|                                                                                           |                |                |                |
|-------------------------------------------------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                                                               | 0 / 25 (0.00%) | 1 / 22 (4.55%) | 0 / 9 (0.00%)  |
| occurrences causally related to treatment / all                                           | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all                                                | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Gastrointestinal disorders</b>                                                         |                |                |                |
| Constipation                                                                              |                |                |                |
| subjects affected / exposed                                                               | 1 / 25 (4.00%) | 0 / 22 (0.00%) | 0 / 9 (0.00%)  |
| occurrences causally related to treatment / all                                           | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                                                | 0 / 0          | 0 / 0          | 0 / 0          |
| Intestinal haemorrhage                                                                    |                |                |                |
| subjects affected / exposed                                                               | 0 / 25 (0.00%) | 0 / 22 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all                                           | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all                                                | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Reproductive system and breast disorders</b>                                           |                |                |                |
| Endometrial hyperplasia                                                                   |                |                |                |
| Additional description: Number at risk has been adjusted as this is a sex-specific event. |                |                |                |
| subjects affected / exposed <sup>[1]</sup>                                                | 0 / 18 (0.00%) | 1 / 16 (6.25%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all                                           | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all                                                | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Skin and subcutaneous tissue disorders</b>                                             |                |                |                |
| Cutaneous calcification                                                                   |                |                |                |
| subjects affected / exposed                                                               | 0 / 25 (0.00%) | 1 / 22 (4.55%) | 0 / 9 (0.00%)  |
| occurrences causally related to treatment / all                                           | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all                                                | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Infections and infestations</b>                                                        |                |                |                |
| COVID-19                                                                                  |                |                |                |
| subjects affected / exposed                                                               | 0 / 25 (0.00%) | 1 / 22 (4.55%) | 0 / 9 (0.00%)  |
| occurrences causally related to treatment / all                                           | 0 / 0          | 1 / 1          | 0 / 0          |
| deaths causally related to treatment / all                                                | 0 / 0          | 0 / 0          | 0 / 0          |
| Escherichia urinary tract infection                                                       |                |                |                |
| subjects affected / exposed                                                               | 0 / 25 (0.00%) | 0 / 22 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all                                           | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all                                                | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Serious adverse events</b>                                                             |                |                |                |
| RCP: Placebo                                                                              |                |                |                |
| Total subjects affected by serious adverse events                                         |                |                |                |

|                                                                     |                |  |  |
|---------------------------------------------------------------------|----------------|--|--|
| subjects affected / exposed                                         | 0 / 13 (0.00%) |  |  |
| number of deaths (all causes)                                       | 0              |  |  |
| number of deaths resulting from adverse events                      |                |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |  |  |
| Breast cancer                                                       |                |  |  |
| subjects affected / exposed                                         | 0 / 13 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0          |  |  |
| deaths causally related to treatment / all                          | 0 / 0          |  |  |
| Vascular disorders                                                  |                |  |  |
| Hypovolaemic shock                                                  |                |  |  |
| subjects affected / exposed                                         | 0 / 13 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0          |  |  |
| deaths causally related to treatment / all                          | 0 / 0          |  |  |
| Cardiac disorders                                                   |                |  |  |
| Coronary artery stenosis                                            |                |  |  |
| subjects affected / exposed                                         | 0 / 13 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0          |  |  |
| deaths causally related to treatment / all                          | 0 / 0          |  |  |
| Cardiac failure                                                     |                |  |  |
| subjects affected / exposed                                         | 0 / 13 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0          |  |  |
| deaths causally related to treatment / all                          | 0 / 0          |  |  |
| Myocardial infarction                                               |                |  |  |
| subjects affected / exposed                                         | 0 / 13 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0          |  |  |
| deaths causally related to treatment / all                          | 0 / 0          |  |  |
| Nervous system disorders                                            |                |  |  |
| Syncope                                                             |                |  |  |
| subjects affected / exposed                                         | 0 / 13 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0          |  |  |
| deaths causally related to treatment / all                          | 0 / 0          |  |  |
| Blood and lymphatic system disorders                                |                |  |  |
| Agranulocytosis                                                     |                |  |  |

|                                                      |                                                                                           |  |  |
|------------------------------------------------------|-------------------------------------------------------------------------------------------|--|--|
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                                            |  |  |
| occurrences causally related to treatment / all      | 0 / 0                                                                                     |  |  |
| deaths causally related to treatment / all           | 0 / 0                                                                                     |  |  |
| Anaemia                                              |                                                                                           |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                                            |  |  |
| occurrences causally related to treatment / all      | 0 / 0                                                                                     |  |  |
| deaths causally related to treatment / all           | 0 / 0                                                                                     |  |  |
| General disorders and administration site conditions |                                                                                           |  |  |
| Impaired healing                                     |                                                                                           |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                                            |  |  |
| occurrences causally related to treatment / all      | 0 / 0                                                                                     |  |  |
| deaths causally related to treatment / all           | 0 / 0                                                                                     |  |  |
| Gastrointestinal disorders                           |                                                                                           |  |  |
| Constipation                                         |                                                                                           |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                                            |  |  |
| occurrences causally related to treatment / all      | 0 / 0                                                                                     |  |  |
| deaths causally related to treatment / all           | 0 / 0                                                                                     |  |  |
| Intestinal haemorrhage                               |                                                                                           |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                                            |  |  |
| occurrences causally related to treatment / all      | 0 / 0                                                                                     |  |  |
| deaths causally related to treatment / all           | 0 / 0                                                                                     |  |  |
| Reproductive system and breast disorders             |                                                                                           |  |  |
| Endometrial hyperplasia                              | Additional description: Number at risk has been adjusted as this is a sex-specific event. |  |  |
| subjects affected / exposed <sup>[1]</sup>           | 0 / 9 (0.00%)                                                                             |  |  |
| occurrences causally related to treatment / all      | 0 / 0                                                                                     |  |  |
| deaths causally related to treatment / all           | 0 / 0                                                                                     |  |  |
| Skin and subcutaneous tissue disorders               |                                                                                           |  |  |
| Cutaneous calcification                              |                                                                                           |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                                            |  |  |
| occurrences causally related to treatment / all      | 0 / 0                                                                                     |  |  |
| deaths causally related to treatment / all           | 0 / 0                                                                                     |  |  |
| Infections and infestations                          |                                                                                           |  |  |
| COVID-19                                             |                                                                                           |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 13 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Escherichia urinary tract infection             |                |  |  |
| subjects affected / exposed                     | 0 / 13 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Number at risk has been adjusted as this is a sex-specific event.

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | RCP: Ravulizumab | OLE: Ravulizumab to Ravulizumab | OLE: Placebo to Ravulizumab |
|-------------------------------------------------------|------------------|---------------------------------|-----------------------------|
| Total subjects affected by non-serious adverse events |                  |                                 |                             |
| subjects affected / exposed                           | 9 / 25 (36.00%)  | 11 / 22 (50.00%)                | 7 / 9 (77.78%)              |
| Vascular disorders                                    |                  |                                 |                             |
| Hypertension                                          |                  |                                 |                             |
| subjects affected / exposed                           | 0 / 25 (0.00%)   | 0 / 22 (0.00%)                  | 0 / 9 (0.00%)               |
| occurrences (all)                                     | 0                | 0                               | 0                           |
| General disorders and administration site conditions  |                  |                                 |                             |
| Pyrexia                                               |                  |                                 |                             |
| subjects affected / exposed                           | 0 / 25 (0.00%)   | 0 / 22 (0.00%)                  | 0 / 9 (0.00%)               |
| occurrences (all)                                     | 0                | 0                               | 0                           |
| Vaccination site swelling                             |                  |                                 |                             |
| subjects affected / exposed                           | 0 / 25 (0.00%)   | 0 / 22 (0.00%)                  | 0 / 9 (0.00%)               |
| occurrences (all)                                     | 0                | 0                               | 0                           |
| Influenza like illness                                |                  |                                 |                             |
| subjects affected / exposed                           | 0 / 25 (0.00%)   | 2 / 22 (9.09%)                  | 0 / 9 (0.00%)               |
| occurrences (all)                                     | 0                | 3                               | 0                           |
| Respiratory, thoracic and mediastinal disorders       |                  |                                 |                             |
| Pulmonary mass                                        |                  |                                 |                             |
| subjects affected / exposed                           | 0 / 25 (0.00%)   | 0 / 22 (0.00%)                  | 1 / 9 (11.11%)              |
| occurrences (all)                                     | 0                | 0                               | 1                           |
| Oropharyngeal pain                                    |                  |                                 |                             |
| subjects affected / exposed                           | 0 / 25 (0.00%)   | 0 / 22 (0.00%)                  | 1 / 9 (11.11%)              |
| occurrences (all)                                     | 0                | 0                               | 1                           |

|                                                                                                                                 |                     |                     |                     |
|---------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Cough<br>subjects affected / exposed<br>occurrences (all)                                                                       | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Vocal cord leukoplakia<br>subjects affected / exposed<br>occurrences (all)                                                      | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Psychiatric disorders<br>Insomnia<br>subjects affected / exposed<br>occurrences (all)                                           | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Injury, poisoning and procedural complications<br>Infusion related reaction<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0 | 2 / 22 (9.09%)<br>2 | 0 / 9 (0.00%)<br>0  |
| Contusion<br>subjects affected / exposed<br>occurrences (all)                                                                   | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Compression fracture<br>subjects affected / exposed<br>occurrences (all)                                                        | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 0 / 9 (0.00%)<br>0  |
| Nervous system disorders<br>Neuralgia<br>subjects affected / exposed<br>occurrences (all)                                       | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 0 / 9 (0.00%)<br>0  |
| Taste disorder<br>subjects affected / exposed<br>occurrences (all)                                                              | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 0 / 9 (0.00%)<br>0  |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 0 / 9 (0.00%)<br>0  |
| Ear and labyrinth disorders<br>Vertigo<br>subjects affected / exposed<br>occurrences (all)                                      | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 0 / 9 (0.00%)<br>0  |
| Eye disorders                                                                                                                   |                     |                     |                     |

|                                                                                 |                      |                     |                     |
|---------------------------------------------------------------------------------|----------------------|---------------------|---------------------|
| Diabetic retinopathy<br>subjects affected / exposed<br>occurrences (all)        | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Gastrointestinal disorders                                                      |                      |                     |                     |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                   | 4 / 25 (16.00%)<br>5 | 0 / 22 (0.00%)<br>0 | 2 / 9 (22.22%)<br>2 |
| Constipation<br>subjects affected / exposed<br>occurrences (all)                | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Anal erosion<br>subjects affected / exposed<br>occurrences (all)                | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Abdominal pain<br>subjects affected / exposed<br>occurrences (all)              | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 0 / 9 (0.00%)<br>0  |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Tongue movement disturbance<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Nausea<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>0 |
| Large intestine polyp<br>subjects affected / exposed<br>occurrences (all)       | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Hypoaesthesia oral<br>subjects affected / exposed<br>occurrences (all)          | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 0 / 9 (0.00%)<br>0  |
| Diverticulum intestinal<br>subjects affected / exposed<br>occurrences (all)     | 0 / 25 (0.00%)<br>0  | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Enterocolitis                                                                   |                      |                     |                     |

|                                                  |                     |                     |                    |
|--------------------------------------------------|---------------------|---------------------|--------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0 | 2 / 22 (9.09%)<br>2 | 0 / 9 (0.00%)<br>0 |
| Skin and subcutaneous tissue disorders           |                     |                     |                    |
| Skin lesion                                      |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 22 (0.00%)      | 0 / 9 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Pruritus                                         |                     |                     |                    |
| subjects affected / exposed                      | 3 / 25 (12.00%)     | 0 / 22 (0.00%)      | 0 / 9 (0.00%)      |
| occurrences (all)                                | 3                   | 0                   | 0                  |
| Eczema                                           |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 22 (0.00%)      | 0 / 9 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Diffuse alopecia                                 |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 22 (0.00%)      | 0 / 9 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Dermatomyositis                                  |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 22 (0.00%)      | 0 / 9 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Endocrine disorders                              |                     |                     |                    |
| Cushingoid                                       |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 22 (0.00%)      | 0 / 9 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Musculoskeletal and connective tissue disorders  |                     |                     |                    |
| Rotator cuff syndrome                            |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 22 (0.00%)      | 1 / 9 (11.11%)     |
| occurrences (all)                                | 0                   | 0                   | 1                  |
| Osteoporosis                                     |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 22 (0.00%)      | 0 / 9 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Myalgia                                          |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 22 (0.00%)      | 0 / 9 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Muscle spasms                                    |                     |                     |                    |
| subjects affected / exposed                      | 0 / 25 (0.00%)      | 0 / 22 (0.00%)      | 0 / 9 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Back pain                                        |                     |                     |                    |

|                                                                                       |                     |                     |                     |
|---------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                      | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)                        | 2 / 25 (8.00%)<br>2 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Infections and infestations                                                           |                     |                     |                     |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 25 (0.00%)<br>0 | 2 / 22 (9.09%)<br>2 | 1 / 9 (11.11%)<br>1 |
| COVID-19<br>subjects affected / exposed<br>occurrences (all)                          | 2 / 25 (8.00%)<br>2 | 2 / 22 (9.09%)<br>2 | 0 / 9 (0.00%)<br>0  |
| Pyoderma<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>0 |
| Nasopharyngitis<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 25 (0.00%)<br>0 | 2 / 22 (9.09%)<br>2 | 0 / 9 (0.00%)<br>0  |
| Influenza<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Genital infection fungal<br>subjects affected / exposed<br>occurrences (all)          | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Sepsis<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>1 |
| Urinary tract infection<br>subjects affected / exposed<br>occurrences (all)           | 0 / 25 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 | 1 / 9 (11.11%)<br>2 |
| Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0 | 2 / 22 (9.09%)<br>2 | 0 / 9 (0.00%)<br>0  |

|                                                       |              |  |  |
|-------------------------------------------------------|--------------|--|--|
| <b>Non-serious adverse events</b>                     | RCP: Placebo |  |  |
| Total subjects affected by non-serious adverse events |              |  |  |

|                                                      |                  |  |  |
|------------------------------------------------------|------------------|--|--|
| subjects affected / exposed                          | 10 / 13 (76.92%) |  |  |
| Vascular disorders                                   |                  |  |  |
| Hypertension                                         |                  |  |  |
| subjects affected / exposed                          | 1 / 13 (7.69%)   |  |  |
| occurrences (all)                                    | 1                |  |  |
| General disorders and administration site conditions |                  |  |  |
| Pyrexia                                              |                  |  |  |
| subjects affected / exposed                          | 1 / 13 (7.69%)   |  |  |
| occurrences (all)                                    | 1                |  |  |
| Vaccination site swelling                            |                  |  |  |
| subjects affected / exposed                          | 1 / 13 (7.69%)   |  |  |
| occurrences (all)                                    | 1                |  |  |
| Influenza like illness                               |                  |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)   |  |  |
| occurrences (all)                                    | 0                |  |  |
| Respiratory, thoracic and mediastinal disorders      |                  |  |  |
| Pulmonary mass                                       |                  |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)   |  |  |
| occurrences (all)                                    | 0                |  |  |
| Oropharyngeal pain                                   |                  |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)   |  |  |
| occurrences (all)                                    | 0                |  |  |
| Cough                                                |                  |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)   |  |  |
| occurrences (all)                                    | 0                |  |  |
| Vocal cord leukoplakia                               |                  |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)   |  |  |
| occurrences (all)                                    | 0                |  |  |
| Psychiatric disorders                                |                  |  |  |
| Insomnia                                             |                  |  |  |
| subjects affected / exposed                          | 0 / 13 (0.00%)   |  |  |
| occurrences (all)                                    | 0                |  |  |
| Injury, poisoning and procedural complications       |                  |  |  |
| Infusion related reaction                            |                  |  |  |
| subjects affected / exposed                          | 1 / 13 (7.69%)   |  |  |
| occurrences (all)                                    | 1                |  |  |

|                                                                                                     |                      |  |  |
|-----------------------------------------------------------------------------------------------------|----------------------|--|--|
| Contusion<br>subjects affected / exposed<br>occurrences (all)                                       | 0 / 13 (0.00%)<br>0  |  |  |
| Compression fracture<br>subjects affected / exposed<br>occurrences (all)                            | 1 / 13 (7.69%)<br>1  |  |  |
| Nervous system disorders<br>Neuralgia<br>subjects affected / exposed<br>occurrences (all)           | 2 / 13 (15.38%)<br>2 |  |  |
| Taste disorder<br>subjects affected / exposed<br>occurrences (all)                                  | 1 / 13 (7.69%)<br>1  |  |  |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all) | 2 / 13 (15.38%)<br>2 |  |  |
| Ear and labyrinth disorders<br>Vertigo<br>subjects affected / exposed<br>occurrences (all)          | 1 / 13 (7.69%)<br>1  |  |  |
| Eye disorders<br>Diabetic retinopathy<br>subjects affected / exposed<br>occurrences (all)           | 0 / 13 (0.00%)<br>0  |  |  |
| Gastrointestinal disorders<br>Diarrhoea<br>subjects affected / exposed<br>occurrences (all)         | 0 / 13 (0.00%)<br>0  |  |  |
| Constipation<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 13 (0.00%)<br>0  |  |  |
| Anal erosion<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 13 (0.00%)<br>0  |  |  |
| Abdominal pain                                                                                      |                      |  |  |

|                                        |                |  |  |
|----------------------------------------|----------------|--|--|
| subjects affected / exposed            | 1 / 13 (7.69%) |  |  |
| occurrences (all)                      | 1              |  |  |
| Vomiting                               |                |  |  |
| subjects affected / exposed            | 0 / 13 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Tongue movement disturbance            |                |  |  |
| subjects affected / exposed            | 0 / 13 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Nausea                                 |                |  |  |
| subjects affected / exposed            | 1 / 13 (7.69%) |  |  |
| occurrences (all)                      | 1              |  |  |
| Large intestine polyp                  |                |  |  |
| subjects affected / exposed            | 0 / 13 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Hypoaesthesia oral                     |                |  |  |
| subjects affected / exposed            | 1 / 13 (7.69%) |  |  |
| occurrences (all)                      | 1              |  |  |
| Diverticulum intestinal                |                |  |  |
| subjects affected / exposed            | 0 / 13 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Enterocolitis                          |                |  |  |
| subjects affected / exposed            | 0 / 13 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Skin and subcutaneous tissue disorders |                |  |  |
| Skin lesion                            |                |  |  |
| subjects affected / exposed            | 1 / 13 (7.69%) |  |  |
| occurrences (all)                      | 1              |  |  |
| Pruritus                               |                |  |  |
| subjects affected / exposed            | 1 / 13 (7.69%) |  |  |
| occurrences (all)                      | 1              |  |  |
| Eczema                                 |                |  |  |
| subjects affected / exposed            | 1 / 13 (7.69%) |  |  |
| occurrences (all)                      | 1              |  |  |
| Diffuse alopecia                       |                |  |  |
| subjects affected / exposed            | 1 / 13 (7.69%) |  |  |
| occurrences (all)                      | 1              |  |  |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                            |  |  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Dermatomyositis<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                                                                                         | 1 / 13 (7.69%)<br>1                                                                                                                                        |  |  |
| Endocrine disorders<br>Cushingoid<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                                                                       | 1 / 13 (7.69%)<br>1                                                                                                                                        |  |  |
| Musculoskeletal and connective tissue disorders<br>Rotator cuff syndrome<br>subjects affected / exposed<br>occurrences (all)<br><br>Osteoporosis<br>subjects affected / exposed<br>occurrences (all)<br><br>Myalgia<br>subjects affected / exposed<br>occurrences (all)<br><br>Muscle spasms<br>subjects affected / exposed<br>occurrences (all)<br><br>Back pain<br>subjects affected / exposed<br>occurrences (all)<br><br>Arthralgia<br>subjects affected / exposed<br>occurrences (all) | 0 / 13 (0.00%)<br>0<br><br>1 / 13 (7.69%)<br>1<br><br>1 / 13 (7.69%)<br>1<br><br>1 / 13 (7.69%)<br>1<br><br>0 / 13 (0.00%)<br>0<br><br>1 / 13 (7.69%)<br>1 |  |  |
| Infections and infestations<br>Bronchitis<br>subjects affected / exposed<br>occurrences (all)<br><br>COVID-19<br>subjects affected / exposed<br>occurrences (all)<br><br>Pyoderma<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                       | 0 / 13 (0.00%)<br>0<br><br>3 / 13 (23.08%)<br>3<br><br>1 / 13 (7.69%)<br>1                                                                                 |  |  |

|                                   |                |  |  |
|-----------------------------------|----------------|--|--|
| Nasopharyngitis                   |                |  |  |
| subjects affected / exposed       | 0 / 13 (0.00%) |  |  |
| occurrences (all)                 | 0              |  |  |
| Influenza                         |                |  |  |
| subjects affected / exposed       | 0 / 13 (0.00%) |  |  |
| occurrences (all)                 | 0              |  |  |
| Genital infection fungal          |                |  |  |
| subjects affected / exposed       | 0 / 13 (0.00%) |  |  |
| occurrences (all)                 | 0              |  |  |
| Sepsis                            |                |  |  |
| subjects affected / exposed       | 0 / 13 (0.00%) |  |  |
| occurrences (all)                 | 0              |  |  |
| Urinary tract infection           |                |  |  |
| subjects affected / exposed       | 1 / 13 (7.69%) |  |  |
| occurrences (all)                 | 1              |  |  |
| Upper respiratory tract infection |                |  |  |
| subjects affected / exposed       | 0 / 13 (0.00%) |  |  |
| occurrences (all)                 | 0              |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date           | Amendment                                                                                                                                                                                                                                                                                         |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 27 August 2021 | <ul style="list-style-type: none"><li>• Provided information on the Independent Data Monitoring Committee (IDMC) role</li><li>• Clarified Part A interim analysis</li><li>• Clarified individual and study closure criteria</li></ul>                                                             |
| 30 August 2022 | <ul style="list-style-type: none"><li>• Broadened the target population</li><li>• Reduced the risk of screen failures</li><li>• Improved participant experience</li><li>• Facilitated recruitment of participants</li></ul>                                                                       |
| 23 June 2023   | <ul style="list-style-type: none"><li>• Extended RCP in Part B from 26 weeks to 50 weeks</li><li>• Extended OLE Period in Part A from 74 weeks to 130 weeks</li><li>• Implemented requirements for conducting a clinical study under European Union Clinical Trials Regulation (EU CTR)</li></ul> |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Part A did not meet its primary endpoint and the study was terminated.

Notes: